29 January 2007 Business
Merck & Co has struck a $460 million (£285 million) deal for rights to certain drug candidates developed by Belgian pharma company Ablynx. Merck will get rights to the monoclonal antibodies found to target a voltage gated ion channel. Ion channels play an important role in a wide range of conditions, but so far no antibody based drug designed to target them has been approved by regulators.
Under the terms of the deal, Merck will pay Ablynx €8.5 million up front, including €2 million for research funding, and agree to pay up to €448 million if and when certain milestones are passed.
Ablynx works with a class of small therapeutic proteins derived from antibodies, which it calls ‘nanobodies’. Each nanobody is the smallest functional fragment of a naturally occurring single chain antibody. The company says these fragments combine the advantages of conventional antibodies with important features of small molecule drugs.
Barium carbonate crystals have been coaxed to form nano-flowers by controlling their chemical environment
31 January 2013 Business
Dicyandiamide poses no food risk but fertiliser companies have suspended sales